Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark

Adv Ther. 2019 Aug;36(8):1817-1820. doi: 10.1007/s12325-019-00990-x. Epub 2019 Jun 1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anemia, Iron-Deficiency*
  • Cost-Benefit Analysis
  • Denmark
  • Disaccharides
  • Ferric Compounds
  • Humans
  • Inflammatory Bowel Diseases*
  • Maltose / analogs & derivatives

Substances

  • Disaccharides
  • Ferric Compounds
  • iron isomaltoside 1000
  • ferric carboxymaltose
  • Maltose

Associated data

  • figshare/10.6084/m9.figshare.7970675